Role of aGVHD Biomarkers on aGVHD Risks

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-07-01

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To establish risk rating criteria of biological protein marker, determine the role and consistency of aGVHD biomarkers in aGVHD diagnosis and aGVHD prognosis, and evaluate the the impact on non-relapse mortality and relapse and disease free survival, the multicenter study on aGVHD biomarkers detection in the patients underwent allogeneic hematopoietic stem cell transplantation was performed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Biomarker Study for Prediction of aGVHD

NCT03614143

aGVHD

UNKNOWN

Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies

NCT06294678

Acute Graft-versus-host Disease

ACTIVE_NOT_RECRUITING PHASE3

Effect of Stem Cell Infusion Time on aGVHD in Patients With Nonmalignant Hematologic Diseases

NCT06294691

Acute Graft-versus-host Disease

RECRUITING PHASE3

Development of a Multi-biomarker Panel for Prognostic Stratification and Treatment Response Prediction in Acute Graft Versus Host Disease of the Gut

NCT07305090

Blood Cancer

RECRUITING

Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study

NCT04372524

Chronic Graft-versus-Host-Disease Leukemia Allogeneic Hematopoietic Stem Cell Transplantation +2 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. To establish standard risk rating criteria of aGVHD biomarkers;
2. To verify the role of aGVHD biomarkers monitored in predicting aGVHD risks;
3. To determine the correlation between aGVHD biomarkers monitored and aGVHD risk;
4. To carry out a observative study in patients with aGVHD treatment about therapeutic protocols and medication efficacy;
5. To predict the correlation between the high-risk patients with aGVHD and non-relapse mortality and disease free survival;

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

GVHD,Acute Biomarker

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

matched sibling hematopoietic stem cell transplantation

aGVHD biomarker in matched sibling donor hematopoietic stem cell transplantation

aGVHD biomarker

Intervention Type DIAGNOSTIC_TEST

To verify the effectiveness of aGVHD biomarkers monitoring in predicting aGVHD risks

unrelated allogeneic hematopoietic stem cell transplantation

aGVHD biomarker in unrelated donor hematopoietic stem cell transplantation

aGVHD biomarker

Intervention Type DIAGNOSTIC_TEST

To verify the effectiveness of aGVHD biomarkers monitoring in predicting aGVHD risks

haploidentical hematopoietic stem cell transplantation

aGVHD biomarker in haploidentical donor hematopoietic stem cell transplantation

aGVHD biomarker

Intervention Type DIAGNOSTIC_TEST

To verify the effectiveness of aGVHD biomarkers monitoring in predicting aGVHD risks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

aGVHD biomarker

To verify the effectiveness of aGVHD biomarkers monitoring in predicting aGVHD risks

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Diagnosed with hematological diseases.
2. Have underwent first allogeneic hematopoietic stem cell transplantation (allo-HSCT) from any donor source using bone marrow, peripheral blood stem cells, or cord blood for hematologic malignancies.

Exclusion Criteria

1. recipients of second allogeneic stem cell transplant.
2. pregnant or breast-feeding women.
3. Serum creatinine \> 2.0 mg/dL or creatinine clearance \< 40 mL/min measured or calculated by Cockroft-Gault equation.
4. human immunodeficiency virus infection
5. active hepatitis b virus, hepatitis C virus infection and need antivirus treatment.
6. Subjects with evidence of relapsed primary disease, or subjects who have been treated for relapse after the allo-HSCT was performed, or graft rejection.
7. allergic history to Janus kinase inhibitors.
8. Severe organ dysfunction unrelated
9. Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the subject; or interfere with interpretation of study data.

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No